Comparison of ceftazidime concentrations in bile and serum.

Antimicrobial Agents and Chemotherapy
E BouzaF Baquero

Abstract

Biliary excretion of ceftazidime, a new broad-spectrum cephalosporin, was studied in two groups of patients after administration of a 2-g dose intravenously. Group A included 10 patients in whom ceftazidime levels in bile were measured during cholecystectomy. Group B included 10 patients with indwelling biliary tubes in whom ceftazidime levels in bile and serum were simultaneously measured at 0.5, 1, 2, 4, 6, and 8 h after administration of the drug. Although ceftazidime levels were variable, they exceeded the minimal inhibitory concentrations of most biliary tract pathogens in both groups.

References

Mar 1, 1979·The Journal of Antimicrobial Chemotherapy·M Severn, S J Powis
Sep 1, 1979·The Journal of Antimicrobial Chemotherapy·M N LoganR P Grimley
Jun 1, 1978·Antimicrobial Agents and Chemotherapy·K R RatzanI Lauredo
Dec 1, 1975·The Surgical Clinics of North America·M R KeighleyJ Alexander-Williams
Nov 1, 1974·American Journal of Surgery·J T Goswitz
Aug 19, 1972·British Medical Journal·J E SalesF O'Grady
Sep 1, 1980·The Journal of Antimicrobial Chemotherapy·J KosmidisG K Daikos

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2021 Meta ULC. All rights reserved